U.S. Personal Products Stock News

Amprius Technologies (AMPX) posted quarterly results that topped Wall Street expectations, as a smaller loss and stronger revenue caught investors’ attention. The report coincided with a record $35 million re-order for its SiCore battery technology, which signals expanding customer demand. See our latest analysis for Amprius Technologies. The buzz around Amprius Technologies is not just about a stellar earnings beat. Momentum has been building for months, with the past 90 days bringing a...

Owens Corning (OC) has come under renewed scrutiny after analyst commentary flagged ongoing weak demand and inventory destocking as major headwinds for the company. These concerns have been echoed by sharply downward revisions in earnings estimates. See our latest analysis for Owens Corning. Owens Corning’s share price has taken a hit in 2025, sliding 33% since the start of the year and reflecting the market’s worries over lackluster demand and recent inventory headwinds. While the stock...

United Bankshares, Inc. recently announced the approval of a new plan to repurchase up to 5 million shares of its common stock and an increase in its annual dividend for 2025. This dual move to expand capital returns highlights management’s ongoing focus on shareholder value and confidence in the company’s outlook. We’ll explore how United Bankshares’ renewed buyback authorization reflects management’s approach to balancing capital management and ongoing investment appeal. This technology...

Atlassian (TEAM) just posted its fiscal Q1 2026 results, delivering cloud and total revenue growth above expectations along with expanding paid seats and record engagement for its AI offerings. However, a lowered billings forecast raises questions about future growth. See our latest analysis for Atlassian. Despite record adoption for its AI offerings and a splashy $2.5 billion buyback announcement, Atlassian’s share price is still feeling the weight of investor wariness, dropping sharply this...

Wondering if Select Medical Holdings is fairly priced, overlooked, or potentially a hidden value? You are not alone, as many investors are eyeing the stock for hints of opportunity. Over the past week, Select Medical has jumped 13.4%, building on an 8.4% gain over the last month, even as it remains down 17.6% year to date. Recent market excitement has been driven by industry-wide discussions about evolving healthcare regulations and strategic partnerships across the sector...

Wondering if Millrose Properties could be a hidden gem or just another overvalued name on the NYSE? You are not alone. Savvy investors know that true value is more than just a stock price. The stock has climbed an impressive 38.8% year-to-date, though it has recently come off its highs with a 5.1% drop over the last month. This kind of movement catches the eye, whether you are chasing momentum or wary of shifting risk. Recent headlines have put Millrose Properties in the...

Linde (NasdaqGS:LIN) has just moved to strengthen its capital base with the issuance of €1.75 billion in new notes, spread across multiple maturities. Investors are already assessing how this fresh debt might shape the company’s financial flexibility in the coming years. See our latest analysis for Linde. Following the announcement of Linde’s new multi-year notes, the share price has hovered near $410, showing little immediate reaction and reflecting a cautious market tone. While the 1-year...

Copart (CPRT) just released its latest quarterly results, showing a bump in both revenue and net income. This improvement is attributed to record US insurance selling prices and stronger auction execution. The company’s ability to boost operating margins is drawing fresh attention from investors. See our latest analysis for Copart. Despite Copart’s recent uptick in operating performance, momentum in the share price has clearly faded. Shares are down roughly 8% over the past month and have...

Ever wondered if Academy Sports and Outdoors stock is trading at a bargain or carrying a hidden premium? You are not alone; investors everywhere are asking whether now is the right time to buy or watch from the sidelines. The stock has caught some attention lately, climbing 9.2% this past week, even as it is still down nearly 15% year-to-date and just about flat over the last year. One reason for the recent moves is sector-wide optimism following positive consumer spending data, which has...

Booking Holdings (BKNG) delivered third-quarter earnings that topped expectations, supported by its Connected Trip strategy, expanding loyalty programs, and AI features. The company also raised its revenue and profit guidance for the rest of the year. See our latest analysis for Booking Holdings. After a year marked by ambitious tech rollouts and upbeat financials, Booking Holdings’ share price sits at $4,914.69. While the 1-year total shareholder return is down 4.8%, longer-term investors...

Thinking about whether Raymond James Financial is worth your investment attention? Let’s dig into what the numbers and some recent events might mean for its true value. The stock has shown some short-term momentum with a 2.3% gain over the past week, though it remains roughly flat year-to-date and is still down 6.3% over the last year after strong gains in the past few years. Recent headlines have focused on Raymond James Financial’s expansion of its wealth management services and strategic...

Ambarella (AMBA) drew extra attention after its fiscal third-quarter results showed a strong year-over-year revenue jump and improved profitability. The company raised its full-year revenue outlook, indicating continued business momentum. See our latest analysis for Ambarella. Even with brisk revenue growth and a raised outlook, Ambarella’s share price has seen sharp swings lately, tumbling nearly 14% over the past 30 days and surrendering much of this quarter’s momentum. Still, longer-term...

Precigen (PGEN) recently received FDA approval for PAPZIMEOS in adults with recurrent respiratory papillomatosis and secured a new credit facility, which extends its cash runway into 2027 and supports its cash flow breakeven goals. See our latest analysis for Precigen. Precigen’s share price story this year has been equally dramatic, with a year-to-date gain of 254.6% following FDA approval news and the extended credit facility. Short-term price swings remain volatile. The company’s 1-year...

If you have ever wondered whether Topgolf Callaway Brands is a bargain, overpriced, or somewhere in between, you are not alone. This article is for you. The stock has been on a tear lately, jumping 27.6% in the past week, 35.7% over the past month, and an eye-catching 53.3% in the last year. This has put growth potential front and center. Much of this momentum can be attributed to a wave of optimism after the company announced new strategic partnerships and high-profile...

Wondering if Mattel is a smart buy right now? If you are curious whether the current stock price means good value, you are in the right place for a deep dive. Mattel’s shares have moved up 6.5% in the past week, gaining 11.0% over the last month and surging 19.1% year-to-date. This signals renewed investor interest and potential growth momentum. Recent headlines spotlight Mattel’s strategic partnerships and new toy releases, including collaborations with Marvel and Disney, which have caught...

McEwen (NYSE:MUX) is back in the spotlight after recent analyst commentary highlighted how the company took advantage of higher gold and silver prices to boost cash flow, even though production decreased last quarter. See our latest analysis for McEwen. McEwen’s momentum has been hard to miss lately, with its 1-day share price jump of 4.2% capping off a run that saw the stock surge 61% over the past 90 days. The company’s year-to-date share price return of 125% and a standout total...

Wondering if Southwest Airlines is a hidden bargain or if the stock price is flying a bit too high? Here is what you should know before making your next move. The stock has been on the move lately, up 6.1% in the past week and gaining 13.5% over the last month. These changes have caught the attention of investors looking for growth or shifts in market sentiment. These recent jumps follow news of changes in the airline industry landscape, including renewed travel demand and updates on...

Curious if PG&E’s share price offers real value right now? You are not alone, as many investors are looking under the hood to see what is driving this utility stock. PG&E shares moved up by 2.9% in the past week and 2.3% over the last month, but they are still down 19.4% year-to-date and 25% over the last twelve months. This hints at lingering uncertainty and changing risk perceptions. Recent headlines have centered around settlement progress related to wildfire liabilities, which has...

MSCI (MSCI) has caught the market’s attention following a fresh round of buy and overweight calls from Wall Street. The company has also seen recent insider share purchases and ongoing executive transitions within the firm. See our latest analysis for MSCI. MSCI has traded in a fairly tight range this year despite policy changes and a continued stream of strategic updates, with the share price hovering near $563.45 and a one-year total shareholder return of -6.4%. While momentum has paused,...

Itron (ITRI) is deepening its international presence by teaming up with Connected Lighting Solutions in Australia to drive smarter urban lighting and by finalizing a significant deployment deal with Northumbrian Water Limited in the UK. See our latest analysis for Itron. Itron’s latest partnerships extend a strong run of international wins, yet these milestones come as the stock is rebounding from a rough patch. After a sharp 28% drop in its 1-month share price return, recent momentum is...

Vertex Pharmaceuticals recently announced updated data from its RUBY-3 trial, showing that povetacicept led to substantial reductions in proteinuria and stabilization of kidney function in patients with IgA nephropathy and primary membranous nephropathy. This candidate is currently the only BAFF+APRIL inhibitor in pivotal kidney disease trials, and Vertex is preparing for a rolling Biologics License Application submission for potential accelerated US FDA approval later this year. We'll...

Several analysts have recently raised their outlook for Liberty Energy (LBRT), while maintaining stable ratings. This highlights shifting investor sentiment and growing interest in the company’s market position and business prospects. See our latest analysis for Liberty Energy. Liberty Energy has shaken things up lately, with the stock jumping 8.5% over the past week after a strong run in the last quarter, even as it remains down year-to-date. Despite a one-year total shareholder return that...

Earlier this week, Argan, Inc. reported eight consecutive quarters of positive results, maintaining a robust financial profile with high institutional investor confidence and a low debt-to-equity ratio. This string of positive financial outcomes has further distinguished Argan within the construction sector, underlining its competitive industry standing and solid operational foundations. To assess how Argan's sustained financial strength influences its investment outlook, we’ll explore the...

ImmunityBio, Inc. recently presented at the Jefferies London Healthcare Conference 2025, sharing updates on its latest performance and product developments at the ME Hotel in London. A noteworthy highlight was the company’s significant third-quarter product revenue growth, driven by strong commercial demand for Anktiva in combination with BCG for BCG-unresponsive NMIBC with CIS. We’ll explore how robust Anktiva product uptake and higher revenue impact ImmunityBio’s investment narrative and...